There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.
Becoming active participants in their own care by understanding treatments and becoming a full partner with their physicians is not the extent to which patients with chronic myelogenous leukemia (CML) can make sure their voices are heard, Giora Sharf, co-founder of the CML Advocates Network, said at the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, California.
In addition to empowering patients by educating them with materials like patient-friendly guidelines to CML treatment, his network is partnered with companies and researchers so the patient voice can be heard during the research and development process and they can be represented throughout the entire process.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity
October 16th 2024Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Read More
Combatting Misconceptions of Clinical Trials to Improve Patient Participation
October 16th 2024There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Read More